![]() |
市場調查報告書
商品編碼
1661058
醫院獲得性疾病檢測市場報告(按適應症(UTI(泌尿道感染)、SSI(手術部位感染)、肺炎、血流感染、MRSA(耐甲氧西林金黃色葡萄球菌)等)和地區分類,2025 年至 2033 年Hospital Acquired Disease Testing Market Report by Indication (UTI (Urinary Tract Infection), SSI (Surgical Site Infection), Pneumonia, Bloodstream Infections, MRSA (Methicillin-Resistant Staphylococcus Aureus), and Others), and Region 2025-2033 |
2024IMARC Group全球醫院內疾病檢測市場規模達到 140 億美元。推動市場發展的因素有幾個,包括老年人口的增加、醫院內獲得性感染(HAI)如泌尿道感染(UTI)、血液感染和肺炎的盛行率增加,以及接受各種外科手術的人數不斷增加。
院內感染 (HAI) 或院內感染是在醫院和醫療診所內感染的疾病。院內感染是指在醫院內發生的感染或疾病。即使在療養院、復健中心、醫院或任何其他臨床環境附近,人們也可能感染此類疾病。大多數人在加護病房 (ICU) 和急診室 (ER) 時感染醫院感染。一般來說,這些疾病的潛伏期為患者入院後的48小時至4天。醫院內感染疾病發生的一個主要原因是醫院內部工作人員缺乏適當的衛生習慣。其他原因可能包括維護水準低於標準、醫院工作人員的自滿以及多重抗藥性細菌 (MDRO) 的增加。一些最常見的院內感染包括肺炎、原發性血流感染、泌尿道感染等。當皮膚保護層接觸到可能的威脅並導致感染時,尤其是在手術後,就會發生這種情況。
在人口成長和醫療基礎設施現代化的推動下,全球醫療設施的數量顯著增加。這導致醫院感染發生率上升,從而推動了醫院內獲得性疾病檢測的需求。此外,隨著技術的進步和科學創新,市場上已經有各種用於預防、診斷和監測醫院感染的技術,例如微陣列、聚合酶鏈反應(PCR)、即時定位系統(RTLS)和固相雜交。 RTLS 等技術可以輕鬆防止醫院感染在患者和工作人員中傳播。患者對醫院感染認知的不斷增強,以及政府頒布法規對醫院感染發病率高的醫院進行懲罰,這些都是催化市場成長的其他因素。
The global hospital acquired disease testing market size reached USD 14.0 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 49.4 Billion by 2033, exhibiting a growth rate (CAGR) of 15% during 2025-2033. There are several factors that are driving the market, which include the rising geriatric population, increasing prevalence of hospital acquired infections (HAIs) like urinary tract infections (UTIs), bloodstream infections, and pneumonia, and the growing number of people undergoing different surgical procedures.
Hospital-acquired infections (HAIs) or nosocomial infections are diseases that are acquired in hospitals and medical clinics. Nosocomial means, infections or diseases originating in a hospital. A person can get such diseases even in the vicinity of a nursing home, rehabilitation center, hospital or any other clinical surroundings. Most people get HAIs when they are in intensive care units (ICUs) and emergency rooms (ERs). Generally, the incubation period of these diseases vary between 48 hours to 4 days after the individual gets admitted. A major reason behind the cause of hospital-acquired diseases is the lack of proper hygiene in the hospital settings by the internal staff. Other reasons can be below-par maintenance, complacency by the hospital staff, and a rise in multi-drug resistant organisms (MDROs). Some of the most commonly occurring nosocomial infections include pneumonia, primary bloodstream infections, urinary tract infections, etc. In many cases, it has also been found that these nosocomial infections are sometimes traced to the patient's own microbiome. It happens when the protective skin layer comes in contact with possible threats and causes infection to occur, especially after surgical operations.
Catalyzed by rising population and modernization of the healthcare infrastructure, there has been a significant increase in the number of health care facilities across the globe. This has resulted in a rising incidence of HAIs, driving the demand of hospital acquired disease tests. Moreover, with advanced technologies and scientific innovations, various techniques are now available in the market for preventing, diagnosing, and monitoring HAIs such as microarrays, polymerase chain reaction (PCR), real time location systems (RTLSs), and solid phase hybridization. Techniques such as RTLS makes it easy to prevent HAIs from spreading in both patients and staff. Growing awareness of HAIs among patients and governments enacting regulations that penalize hospitals having a high incidence of HAIs are some of the other factors that are catalyzing the growth of the market.
Based on the indication, the market has been segmented into urinary tract infection, surgical site infection, pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus and others. Urinary tract infection currently represents the biggest segment.